At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
Pazopanibdrug
Likely dose
Pazopanib 800mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective International Multicenter Phase II Study to Evaluate the Efficacy, Safety and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Previous Therapy With Checkpoint Inhibitor Treatment
In Brief
A Phase 2 clinical trial evaluating Pazopanib for Advanced Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma. Completed, enrolled 62 participants across 22 sites in 11 countries.
Detailed Summary
The main purpose of this study was to assess the progression-free survival (PFS) based on local investigator assessment of pazopanib in participants with advanced and/or metastatic renal cell carcinoma (mRCC) following prior treatment with immune checkpoint inhibitors (ICI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Austria, Canada, Chile, Czechia, France, Germany, Hungary, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartNov 2017
Primary CompletionAug 2021
TodayJul 2026
First PostedJun 27, 2017
Enrollment StartNov 14, 2017
Primary CompletionAug 10, 2021
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 9.0 years ago
Interventions
Pazopanibdrug
Participants received 800mg of pazopanib once daily orally. Pazopanib was supplied as aqueous film-coated tablets containing 200 mg or 400 mg.